Literature DB >> 35990029

Importance of Immediate Thiamine Therapy in Children with Suspected Thiamine-Responsive Megaloblastic Anemia-Report on Two Patients Carrying a Novel SLC19A2 Gene Mutation.

Anita Spehar Uroic1, Dragan Milenkovic2, Elisa De Franco3, Ernest Bilic4, Natasa Rojnic Putarek5, Nevena Krnic4.   

Abstract

Thiamine-responsive megaloblastic anemia (TRMA) is an autosomal recessive disorder characterized by the development of megaloblastic anemia, diabetes mellitus, and sensorineural deafness. We report on the first two Croatian patients with TRMA, compound heterozygotes for nonsense, c.373C > T; p.(Gln125Ter) and novel missense variant, c.1214C > G; p.(Thr405Arg) in SLC19A2 gene. The first was diagnosed at 4 months with diabetes mellitus and severe anemia requiring transfusions. As TRMA was suspected, thiamine therapy was immediately started to prevent further transfusions and insulin therapy. His brother developed extreme anemia at 3 weeks of age while waiting for the results of the genetic test. Severe anemia in this sibling may have been prevented if thiamine had been initiated earlier. Thieme. All rights reserved.

Entities:  

Keywords:  SLC19A2 gene ; neonatal diabetes mellitus; thiamine-responsive megaloblastic anemia

Year:  2020        PMID: 35990029      PMCID: PMC9385258          DOI: 10.1055/s-0040-1717136

Source DB:  PubMed          Journal:  J Pediatr Genet        ISSN: 2146-460X


  11 in total

Review 1.  Recessive SLC19A2 mutations are a cause of neonatal diabetes mellitus in thiamine-responsive megaloblastic anaemia.

Authors:  Charles Shaw-Smith; Sarah E Flanagan; Ann-Marie Patch; Juergen Grulich-Henn; Abdelhadi M Habeb; Khalid Hussain; Renata Pomahacova; Krystyna Matyka; Mohamed Abdullah; Andrew T Hattersley; Sian Ellard
Journal:  Pediatr Diabetes       Date:  2012-02-27       Impact factor: 4.866

2.  Beta cell function and clinical course in three siblings with thiamine-responsive megaloblastic anemia (TRMA) treated with thiamine supplementation.

Authors:  Kathryn Potter; John Wu; Julie Lauzon; Josephine Ho
Journal:  J Pediatr Endocrinol Metab       Date:  2017-02-01       Impact factor: 1.634

3.  Deletion of SLC19A2, the high affinity thiamine transporter, causes selective inner hair cell loss and an auditory neuropathy phenotype.

Authors:  M C Liberman; E Tartaglini; J C Fleming; E J Neufeld
Journal:  J Assoc Res Otolaryngol       Date:  2006-04-27

4.  Thiamine-responsive megaloblastic anemia.

Authors:  F S Porter; L E Rogers; J B Sidbury
Journal:  J Pediatr       Date:  1969-04       Impact factor: 4.406

5.  Thiamine-responsive megaloblastic anemia syndrome (TRMA) with cone-rod dystrophy.

Authors:  F M Meire; K Lemmens; M H Ens-Dokkum
Journal:  Ophthalmic Genet       Date:  2000-12       Impact factor: 1.803

6.  Thiamine responsive megaloblastic anemia syndrome: a novel homozygous SLC19A2 gene mutation identified.

Authors:  Violeta Mikstiene; Jurgita Songailiene; Jekaterina Byckova; Giedre Rutkauskiene; Edita Jasinskiene; Rasa Verkauskiene; Eugenijus Lesinskas; Algirdas Utkus
Journal:  Am J Med Genet A       Date:  2015-02-23       Impact factor: 2.802

7.  Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation update.

Authors:  Anke K Bergmann; Inderneel Sahai; Jill F Falcone; Judy Fleming; Adam Bagg; Caterina Borgna-Pignati; Robin Casey; Luca Fabris; Elizabeth Hexner; Lulu Mathews; Maria Leticia Ribeiro; Klaas J Wierenga; Ellis J Neufeld
Journal:  J Pediatr       Date:  2009-07-29       Impact factor: 4.406

8.  Thiamine-responsive megaloblastic anemia: early diagnosis may be effective in preventing deafness.

Authors:  Hasan Onal; Safa Bariş; Mine Ozdil; Gözde Yeşil; Gürkan Altun; Isa Ozyilmaz; Ahmet Aydin; Tiraje Celkan
Journal:  Turk J Pediatr       Date:  2009 May-Jun       Impact factor: 0.552

9.  Cone-rod dystrophy in thiamine-responsive megaloblastic anemia.

Authors:  A Kipioti; N D L George; A V Hoffbrand; Eammond Sheridan
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2003 Mar-Apr       Impact factor: 1.402

10.  Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome.

Authors:  Abdelhadi M Habeb; Sarah E Flanagan; Mohamed A Zulali; Mohamed A Abdullah; Renata Pomahačová; Veselin Boyadzhiev; Lesby E Colindres; Guillermo V Godoy; Thiruvengadam Vasanthi; Ramlah Al Saif; Aria Setoodeh; Amirreza Haghighi; Alireza Haghighi; Yomna Shaalan; Andrew T Hattersley; Sian Ellard; Elisa De Franco
Journal:  Diabetologia       Date:  2018-02-15       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.